1. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non‐small cell lung cancer: A systematic analysis and meta‐analysis based on randomized controlled trials. (8th June 2021) Authors: Liu, Qiangyun; Fang, Zige; Liu, Miaowen; Xu, Ruoxin; Yi, Fengming; Wei, Yiping; Zeng, Linxiang; Zhang, Wenxiong Journal: Journal of clinical pharmacy and therapeutics Issue: Volume 46:Number 6(2021) Page Start: 1519 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non‐small cell lung cancer: A meta‐analysis of randomized controlled trials. (6th October 2021) Authors: Liu, Miaowen; Luo, Nachuan; Fang, Zige; Liu, Qiangyun; Yi, Fengming; Wei, Yiping; Zhang, Xinyi; Zhang, Wenxiong Journal: Journal of clinical pharmacy and therapeutics Issue: Volume 47:Number 2(2022) Page Start: 157 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗